Breaking News

Anavex Appoints Clinical Ops VP

August 7, 2014

Wyeth veteran to head clinical programs

Tasos Zografidis, Ph.D. has been appointed vice president of Clinical Operations at Anavex Life Sciences Corp. In this newly created position, Dr. Zografidis will be responsible for managing Anavex's clinical programs, including the upcoming Phase IIa trial for ANAVEX 2-73 and ANAVEX PLUS, the company's lead drug candidate combination for Alzheimer's disease.
 
Dr. Zografidis has more than 25 years of experience in the pharma and healthcare industry, having spent 12 years at Wyeth in clinical project management and most recently served as a clinical and pharmaceutical consultant. At Wyeth, Dr. Zografidis spearheaded population pharmacokinetics analysis and its implementation in the clinical setting and positively differentiated compounds. Dr. Zografidis first joined Wyeth in 1998 as a product manager.  
 
"Dr. Zografidis is a tremendous addition to our management team and I am very pleased to welcome him to Anavex," said Christopher U. Missling, Ph.D., president and chief executive officer of Anavex.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks